194 related articles for article (PubMed ID: 29743049)
1. Cost implications of PSA screening differ by age.
Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE
BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
[TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
4. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
Krahn MD; Coombs A; Levy IG
CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
[TBL] [Abstract][Full Text] [Related]
5. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
Heijnsdijk EA; Denham D; de Koning HJ
Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
[TBL] [Abstract][Full Text] [Related]
6. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
Zanwar P; Lin YL; Kuo YF; Goodwin JS
BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
[TBL] [Abstract][Full Text] [Related]
7. The socioeconomic implications of prostate-specific antigen screening.
Benoit RM; Naslund MJ
Urol Clin North Am; 1997 May; 24(2):451-8. PubMed ID: 9126243
[TBL] [Abstract][Full Text] [Related]
8. The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice.
Lao C; Brown C; Obertová Z; Edlin R; Rouse P; Hodgson F; Holmes M; Gilling P; Lawrenson R
Fam Pract; 2013 Dec; 30(6):641-7. PubMed ID: 24055993
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
11. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.
Kim SP; Karnes RJ; Gross CP; Meropol NJ; Van Houten H; Abouassaly R; Shah ND
Urology; 2016 Nov; 97():111-117. PubMed ID: 27527411
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
[TBL] [Abstract][Full Text] [Related]
13. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
17. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
[TBL] [Abstract][Full Text] [Related]
18. Optimal Starting Age and Baseline Level for Repeat Tests: Economic Concerns of PSA Screening for Chinese Men - 10-Year Experience of a Single Center.
Liu Y; Xiao G; Zhou JW; Yang JK; Lu L; Bian J; Zhong L; Wei QZ; Zhou QZ; Xue KY; Guo WB; Xia M; Zhou JH; Bao JM; Yang C; Liu CD; Chen MK
Urol Int; 2020; 104(3-4):230-238. PubMed ID: 31770767
[TBL] [Abstract][Full Text] [Related]
19. Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program.
Uozumi J; Tokuda Y; Fujiyama C; Takagi N; Meiri H; Kuratomi K; Nakamura K; Ichigi Y; Yoshinaga H; Kinoshita N; Masaki Z
Int J Urol; 2002 Jun; 9(6):334-9. PubMed ID: 12110098
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer screening trends in a large, integrated health care system.
Wallner L; Frencher S; Hsu JW; Loo R; Huang J; Nichol M; Jacobsen S
Perm J; 2012; 16(3):4-9. PubMed ID: 23012592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
